South Korea's Financial Supervisory Service (FSS) will hold four September briefings to support implementation of its comprehensive pharmaceutical and biotech disclosure improvement plan. The sessions will target KOSDAQ-listed companies on September 1, underwriters on September 8, IPO preparation companies on September 15, and KOSPI-listed companies on September 21. The plan requires more detailed documentation of IPO pricing assumptions, including projected market size, clinical-trial success probability, regulatory approval and review risks, and development timelines and costs. It also expands disclosure requirements for technology-transfer agreements to cover contract structure, upfront payments, development milestones, regulatory approval and sales milestones, and royalties. Other measures include a comprehensive history management table for drug candidates, stronger links between disclosures, explanatory notes for technical terms, and rules requiring important information to be disclosed through official channels before media reports. The FSS said the briefings aim to improve disclosure quality, reduce correction requests and limit fundraising delays caused by inadequate filings.